📊 VICP Key Takeaways
Is Vicapsys Life Sciences, Inc. (VICP) a Good Investment?
Vicapsys Life Sciences exhibits critical financial distress with negative stockholders equity of -2.6M, indicating technical insolvency. The company has no reported revenue, ongoing substantial losses (-752.7K net income), catastrophic liquidity (0.03x current ratio), and only 89.6K in cash against significant obligations, creating an imminent solvency crisis.
Why Buy Vicapsys Life Sciences, Inc. Stock? VICP Key Strengths
- Minimal operational debt structure despite negative equity
- Still trading and operational, allowing potential for capital restructuring
- Pharmaceutical sector exposure could offer significant upside if any product-related assets emerge
VICP Stock Risks: Vicapsys Life Sciences, Inc. Investment Risks
- Negative stockholders equity of -2.6M indicating technical insolvency and liabilities exceed assets
- Critical liquidity crisis with 0.03x current ratio and only 89.6K cash against substantial current liabilities
- No reported revenue and persistent large losses (-752.7K net income, -585.0K operating loss) with negative free cash flow burning capital
- Imminent cash depletion risk given minimal cash position and ongoing negative cash burn of -43.7K
- Zero insider Form 4 activity suggests management has no confidence in company viability
- High probability of bankruptcy filing or dilutive emergency capital raise to avoid insolvency
Key Metrics to Watch
- Cash burn rate and remaining runway in weeks/months before depletion
- Any revenue generation or commercial partnership announcements
- Changes in stockholders equity trajectory toward positive territory
- Emergency capital raises, debt restructuring, or bankruptcy filings
- Patent filings or disclosed development-stage assets in SEC filings
Vicapsys Life Sciences, Inc. (VICP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
VICP Profit Margin, ROE & Profitability Analysis
VICP vs Healthcare Sector: How Vicapsys Life Sciences, Inc. Compares
How Vicapsys Life Sciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vicapsys Life Sciences, Inc. Stock Overvalued? VICP Valuation Analysis 2026
Based on fundamental analysis, Vicapsys Life Sciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vicapsys Life Sciences, Inc. Balance Sheet: VICP Debt, Cash & Liquidity
VICP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vicapsys Life Sciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.03 indicates the company is currently unprofitable.
VICP Revenue Growth, EPS Growth & YoY Performance
Vicapsys Life Sciences, Inc. Dividends, Buybacks & Capital Allocation
VICP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vicapsys Life Sciences, Inc. (CIK: 0001468639)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VICP
What is the AI rating for VICP?
Vicapsys Life Sciences, Inc. (VICP) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VICP's key strengths?
Claude: Minimal operational debt structure despite negative equity. Still trading and operational, allowing potential for capital restructuring.
What are the risks of investing in VICP?
Claude: Negative stockholders equity of -2.6M indicating technical insolvency and liabilities exceed assets. Critical liquidity crisis with 0.03x current ratio and only 89.6K cash against substantial current liabilities.
What is VICP's revenue and growth?
Vicapsys Life Sciences, Inc. reported revenue of N/A.
Does VICP pay dividends?
Vicapsys Life Sciences, Inc. does not currently pay dividends.
Where can I find VICP SEC filings?
Official SEC filings for Vicapsys Life Sciences, Inc. (CIK: 0001468639) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VICP's EPS?
Vicapsys Life Sciences, Inc. has a diluted EPS of $-0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VICP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Vicapsys Life Sciences, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VICP stock overvalued or undervalued?
Valuation metrics for VICP: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VICP stock in 2026?
Our dual AI analysis gives Vicapsys Life Sciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VICP's free cash flow?
Vicapsys Life Sciences, Inc.'s operating cash flow is $-43.7K, with capital expenditures of N/A.
How does VICP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.03 (avg: 2).